Axentri

Axentri Uses, Dosage, Side Effects, Food Interaction and all others data.

Axentri (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Axentri name as it entered trials. It was approved for use by the FDA in August, 2007.

Axentri is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5.

Trade Name Axentri
Availability Prescription only
Generic Maraviroc
Maraviroc Other Names Maraviroc, Maravirocum
Related Drugs Biktarvy, Truvada, tenofovir, ritonavir, Complera, Atripla, Stribild
Weight 150mg
Type Tablet
Formula C29H41F2N5O
Weight Average: 513.6655
Monoisotopic: 513.327917369
Protein binding

Approximately 76% bound to human plasma proteins, with moderate affinity for albumin and alpha-1 acid glycoprotein.

Groups Approved, Investigational
Therapeutic Class
Manufacturer Emcure Pharmaceuticals Ltd
Available Country India
Last Updated: September 19, 2023 at 7:00 am
Axentri
Axentri

Uses

Axentri is a CCR5 co-receptor antagonist used with other antiretroviral medications to treat CCR5-tropic HIV-1 infection.

For treatment-experienced adult patients infected with only CCR5-tropic HIV-1 detectable, who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents.

Axentri is also used to associated treatment for these conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection

How Axentri works

Axentri is an entry inhibitor and works by blocking HIV from entering human cells. Specifically maraviroc is a selective, slowly reversible, small molecule antagonist of the interaction between human CCR5 and HIV-1 gp120. Axentri selectively binds to the human chemokine receptor CCR5 present on the membrane of CD4 cells (T-cells), preventing the interaction of HIV-1 gp120 and CCR5 necessary for CCR5-tropic HIV-1 to enter cells.

Food Interaction

  • Avoid St. John's Wort. This herb induces CYP3A metabolism and may reduce serum levels of maraviroc.
  • Take with or without food.

[Minor] Administration with food may reduce the bioavailability of maraviroc.

According to the product labeling, coadministration of a 300 mg dose of maraviroc with a high-fat breakfast reduced maraviroc peak plasma concentration (Cmax) and systemic exposure (AUC) by 33% in healthy volunteers.

However, no food restrictions were used in the clinical studies that demonstrated the safety and efficacy of maraviroc.

Therefore, maraviroc can be taken with or without food at the recommended dosage.

Volume of Distribution

  • 194 L

Elimination Route

The absolute oral bioavailability of a 100 mg dose is 23% and is predicted to be 33% at 300 mg. Coadministration of a 300mg tablet with a high fat breakfast reduced maraviroc Cmax and AUC by 33% in healthy volunteers.

Half Life

14-18 hours

Innovators Monograph

You find simplified version here Axentri

*** Taking medicines without doctor's advice can cause long-term problems.
Share